^
    over1year
    Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (clinicaltrials.gov)
    P1/2, N=150, Enrolling by invitation, Shanghai YingLi Pharmaceutical Co. Ltd. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
    |
    YL-15293
    almost2years
    Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (clinicaltrials.gov)
    P1/2, N=150, Enrolling by invitation, Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting --> Enrolling by invitation | N=90 --> 150 | Trial primary completion date: Nov 2022 --> Apr 2023
    Enrollment open • Enrollment change • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12
    |
    YL-15293
    almost3years
    A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability)
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12
    |
    YL-15293
    3years
    A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
    Clinical • New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    YL-15293